Whereas treatment for localized CRC rely on surgery and chemotherapy, therapeutic strategies in metastatic setting were improved through the development of biomarkers for targeted therapies, such as EGFR (epithelial growth factor receptor) inhibitors, BRAF serine/threonine-protein kinase B-Raf) inhibitors, HER2 (human epidermal growth factor receptor 2) inhibitors, immune checkpoint inhibitors, or NTRK (neurotrophic tyrosine receptor kinase) inhibitors. This evidence concerns the gene BRAF and colorectal carcinoma.